Liver Cancers pp 277-293 | Cite as

Colorectal Liver Metastasis

  • Rafael Diaz-NietoEmail author
  • Graeme J. Poston


Colorectal cancer is the third most common cause of cancer in both men and women. The liver represents the most common site for distant metastases in colorectal cancer, and more than 60% of the patients will develop liver metastases during the course of the disease. Colorectal liver metastases were traditionally considered incurable, and patients were managed in a palliative manner only. This is no longer the case, and there is evidence suggesting that interventions to the liver metastases can achieve long-term survival benefits, both in terms of overall and disease-free survival. The management of colorectal liver metastases has become a very complex multidisciplinary process. This complexity relies on more detailed diagnoses, careful preoperative assessment and multidisciplinary approaches with combinations of systemic treatments and locoregional treatments to the liver. This chapter describes the main aspects of the diagnostic and therapeutic strategies available and provides an overview of the current management of colorectal liver metastases.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Sag AA, Selcukbiricik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol. 2016;22(11):3127–49.CrossRefGoogle Scholar
  3. 3.
    Rudmik LR, Magliocco AM. Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol. 2005;92(4):347–59.CrossRefGoogle Scholar
  4. 4.
    Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer. 2007;121(9):2005–12.CrossRefGoogle Scholar
  5. 5.
    Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, et al. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. J Transl Med. 2016;14(1):292.CrossRefGoogle Scholar
  6. 6.
    Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, Chung MH, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg. 2017.Google Scholar
  7. 7.
    Andreatos N, Ronnekleiv-Kelly S, Margonis GA, Sasaki K, Gani F, Amini N, et al. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. Surg Oncol. 2016;25(3):332–8.CrossRefGoogle Scholar
  8. 8.
    Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;99:150–7.CrossRefGoogle Scholar
  9. 9.
    Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–83.CrossRefGoogle Scholar
  10. 10.
    Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep. 2015;5:8065.CrossRefGoogle Scholar
  11. 11.
    Allard MA, Adam R, Giuliante F, Lapointe R, Hubert C, Ijzermans JNM, et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer. 2017;117(5):604–11.CrossRefGoogle Scholar
  12. 12.
    Torzilli G, Procopio F. State of the art of intraoperative ultrasound in liver surgery: current use for resection-guidance. Chirurgia (Bucur). 2017;112(3):320–5.CrossRefGoogle Scholar
  13. 13.
    Cantisani V, Ricci P, Erturk M, Pagliara E, Drudi F, Calliada F, et al. Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue(R) low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. Ultraschall Med. 2010;31(5):500–5.CrossRefGoogle Scholar
  14. 14.
    Cantisani V, Grazhdani H, Fioravanti C, Rosignuolo M, Calliada F, Messineo D, et al. Liver metastases: contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World J Gastroenterol. 2014;20(29):9998–10007.CrossRefGoogle Scholar
  15. 15.
    Hale HL, Husband JE, Gossios K, Norman AR, Cunningham D. CT of calcified liver metastases in colorectal carcinoma. Clin Radiol. 1998;53(10):735–41.CrossRefGoogle Scholar
  16. 16.
    Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci. 2007;6(1):43–52.CrossRefGoogle Scholar
  17. 17.
    van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805–13.CrossRefGoogle Scholar
  18. 18.
    Xia Q, Liu J, Wu C, Song S, Tong L, Huang G, et al. Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging. 2015;15:19.CrossRefGoogle Scholar
  19. 19.
    Yip VS, Poston GJ, Fenwick SW, Wieshmann H, Athwal T, Malik HZ. FDG-PET-CT is effective in selecting patients with poor long term survivals for colorectal liver metastases. Eur J Surg Oncol. 2014;40(8):995–9.CrossRefGoogle Scholar
  20. 20.
    Lee DH, Lee JM. Whole-body PET/MRI for colorectal cancer staging: is it the way forward? J Magn Reson Imaging. 2017;45(1):21–35.CrossRefGoogle Scholar
  21. 21.
    Yip VS, Collins B, Dunne DF, Koay MY, Tang JM, Wieshmann H, et al. Optimal imaging sequence for staging in colorectal liver metastases: analysis of three hypothetical imaging strategies. Eur J Cancer. 2014;50(5):937–43.CrossRefGoogle Scholar
  22. 22.
    Wilson SM, Adson MA. Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg. 1976;111(4):330–4.CrossRefGoogle Scholar
  23. 23.
    Hosokawa I, Allard MA, Gelli M, Ciacio O, Vibert E, Cherqui D, et al. Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol. 2016;23(6):1897–905.CrossRefGoogle Scholar
  24. 24.
    Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110(1):13–29.PubMedGoogle Scholar
  25. 25.
    Moris D, Tsilimigras DI, Chakedis J, Beal EW, Felekouras E, Vernadakis S, et al. Liver transplantation for unresectable colorectal liver metastases: a systematic review. J Surg Oncol. 2017;116(3):288–97.CrossRefGoogle Scholar
  26. 26.
    Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619–26.CrossRefGoogle Scholar
  27. 27.
    Ruers T, Punt CJA, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, Poston G, et al. Long-term survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM intergroup 40004 (CLOCC). J Clin Oncol. 2015;33(Suppl).Google Scholar
  28. 28.
    Hallet J, Beyfuss K, Memeo R, Karanicolas PJ, Marescaux J, Pessaux P. Short and long-term outcomes of laparoscopic compared to open liver resection for colorectal liver metastases. Hepatobiliary Surg Nutr. 2016;5(4):300–10.CrossRefGoogle Scholar
  29. 29.
    Tanaka K, Murakami T, Yabushita Y, Hiroshima Y, Matsuo K, Endo I, et al. Maximal debulking liver resection as a beneficial treatment strategy for advanced and aggressive colorectal liver metastases. Anticancer Res. 2014;34(10):5547–54.PubMedGoogle Scholar
  30. 30.
    de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248(4):626–37.PubMedGoogle Scholar
  31. 31.
    Truant S, Sequier C, Leteurtre E, Boleslawski E, Elamrani M, Huet G, et al. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford). 2015;17(2):176–84.CrossRefGoogle Scholar
  32. 32.
    Tranchart H, Chirica M, Faron M, Balladur P, Lefevre LB, Svrcek M, et al. Prognostic impact of positive surgical margins after resection of colorectal cancer liver metastases: reappraisal in the era of modern chemotherapy. World J Surg. 2013;37(11):2647–54.CrossRefGoogle Scholar
  33. 33.
    Alvarez FA, Sanchez Claria R, Oggero S, de Santibanes E. Parenchymal-sparing liver surgery in patients with colorectal carcinoma liver metastases. World J Gastrointest Surg. 2016;8(6):407–23.CrossRefGoogle Scholar
  34. 34.
    Moris D, Ronnekleiv-Kelly S, Kostakis ID, Tsilimigras DI, Beal EW, Papalampros A, et al. Operative results and oncologic outcomes of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) versus Two-Stage Hepatectomy (TSH) in patients with unresectable colorectal liver metastases: a systematic review and meta-analysis. World J Surg. 2017.Google Scholar
  35. 35.
    Ironside N, Bell R, Bartlett A, McCall J, Powell J, Pandanaboyana S. Systematic review of perioperative and survival outcomes of liver resections with and without preoperative portal vein embolization for colorectal metastases. HPB (Oxford). 2017;19(7):559–66.CrossRefGoogle Scholar
  36. 36.
    Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford). 2013;15(7):483–91.CrossRefGoogle Scholar
  37. 37.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.CrossRefGoogle Scholar
  38. 38.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.CrossRefGoogle Scholar
  39. 39.
    Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol. 2006;24(31):4954–5.CrossRefGoogle Scholar
  40. 40.
    Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–5.CrossRefGoogle Scholar
  41. 41.
    Fiorentini G, Sarti D, Aliberti C, Carandina R, Mambrini A, Guadagni S. Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol. 2017;8(3):190–202.CrossRefGoogle Scholar
  42. 42.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.CrossRefGoogle Scholar
  43. 43.
    Araujo RL, Gonen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(9):3070–8.CrossRefGoogle Scholar
  44. 44.
    Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20(12):1964–70.CrossRefGoogle Scholar
  45. 45.
    Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer. 2009;101(7):1033–8.CrossRefGoogle Scholar
  46. 46.
    Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22(9):2042–8.CrossRefGoogle Scholar
  47. 47.
    Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3(7):e170278.CrossRefGoogle Scholar
  48. 48.
    Lv W, Zhang GQ, Jiao A, Zhao BC, Shi Y, Chen BM, et al. Chemotherapy plus cetuximab versus chemotherapy alone for patients with KRAS wild type unresectable liver-confined metastases colorectal cancer: an updated meta-analysis of RCTs. Gastroenterol Res Pract. 2017;2017:8464905.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World J Gastroenterol. 2014;20(24):7602–21.CrossRefGoogle Scholar
  50. 50.
    Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, et al. A comparison of Yttrium-90 microsphere radioembolization to hepatic arterial infusional chemotherapy for patients with chemo-refractory hepatic colorectal metastases. Curr Treat Options in Oncol. 2017;18(7):42.CrossRefGoogle Scholar
  51. 51.
    Bhutiani N, Martin RC 2nd. Transarterial therapy for colorectal liver metastases. Surg Clin North Am. 2016;96(2):369–91.CrossRefGoogle Scholar
  52. 52.
    Jones RP, Malik HZ, Fenwick SW, Terlizzo M, O'Grady E, Stremitzer S, et al. PARAGON II—a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol. 2016;42(12):1866–72.CrossRefGoogle Scholar
  53. 53.
    Wu ZB, Si ZM, Qian S, Liu LX, Qu XD, Zhou B, et al. Percutaneous microwave ablation combined with synchronous transcatheter arterial chemoembolization for the treatment of colorectal liver metastases: results from a follow-up cohort. Onco Targets Ther. 2016;9:3783–9.CrossRefGoogle Scholar
  54. 54.
    Poston G. Cryosurgery for colorectal liver metastases. Hepato-Gastroenterology. 2001;48(38):323–4.PubMedGoogle Scholar
  55. 55.
    Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, et al. Ablative therapies for colorectal liver metastases: a systematic review. Color Dis. 2011;13(9):e252–65.CrossRefGoogle Scholar
  56. 56.
    Correa-Gallego C, Fong Y, Gonen M, D'Angelica MI, Allen PJ, DeMatteo RP, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014;21(13):4278–83.CrossRefGoogle Scholar
  57. 57.
    Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17(1):171–8.CrossRefGoogle Scholar
  58. 58.
    Scheffer HJ, Melenhorst MC, Echenique AM, Nielsen K, van Tilborg AA, van den Bos W, et al. Irreversible electroporation for colorectal liver metastases. Tech Vasc Interv Radiol. 2015;18(3):159–69.CrossRefGoogle Scholar
  59. 59.
    Hammill CW, Billingsley KG, Cassera MA, Wolf RF, Ujiki MB, Hansen PD. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol. 2011;18(7):1947–54.CrossRefGoogle Scholar
  60. 60.
    Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK. Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res. 2006;26(1B):671–80.PubMedGoogle Scholar
  61. 61.
    Diaz-Nieto R, Fenwick S, Malik H, Poston G. Defining the optimal use of ablation for metastatic colorectal cancer to the liver without high-level evidence. Curr Treat Options in Oncol. 2017;18(2):8.CrossRefGoogle Scholar
  62. 62.
    Gillams A, Goldberg N, Ahmed M, Bale R, Breen D, Callstrom M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontieres meeting 2013. Eur Radiol. 2015;25(12):3438–54.CrossRefGoogle Scholar
  63. 63.
    de Meijer VE, Verhoef C, Kuiper JW, Alwayn IP, Kazemier G, Ijzermans JN. Radiofrequency ablation in patients with primary and secondary hepatic malignancies. J Gastrointest Surg. 2006;10(7):960–73.CrossRefGoogle Scholar
  64. 64.
    Wu YZ, Li B, Wang T, Wang SJ, Zhou YM. Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol. 2011;17(36):4143–8.CrossRefGoogle Scholar
  65. 65.
    Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25. discussion 25-7CrossRefGoogle Scholar
  66. 66.
    Lee KH, Kim HO, Yoo CH, Son BH, Park YL, Cho YK, et al. Comparison of radiofrequency ablation and resection for hepatic metastasis from colorectal cancer. Korean J Gastroenterol. 2012;59(3):218–23.CrossRefGoogle Scholar
  67. 67.
    Lee H, Heo JS, Cho YB, Yun SH, Kim HC, Lee WY, et al. Hepatectomy vs radiofrequency ablation for colorectal liver metastasis: a propensity score analysis. World J Gastroenterol. 2015;21(11):3300–7.CrossRefGoogle Scholar
  68. 68.
    Hagness M, Foss A, Line PD, Scholz T, Jorgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257(5):800–6.CrossRefGoogle Scholar
  69. 69.
    Wurster EF, Tenckhoff S, Probst P, Jensen K, Dolger E, Knebel P, et al. A systematic review and meta-analysis of the utility of repeated versus single hepatic resection for colorectal cancer liver metastases. HPB (Oxford). 2017;19(6):491–7.CrossRefGoogle Scholar
  70. 70.
    Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238(6):871–83. discussion 83-4CrossRefGoogle Scholar
  71. 71.
    Dupre A, Jones R, Diaz-Nieto R, Fenwick S, Poston G, Malik H. Curative-intent treatment of recurrent colorectal liver metastases: a comparison between ablation and resection. Eur J Surg Oncol. 2017;43(10):1901–7.CrossRefGoogle Scholar
  72. 72.
    Hadden WJ, de Reuver PR, Brown K, Mittal A, Samra JS, Hugh TJ. Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford). 2016;18(3):209–20.CrossRefGoogle Scholar
  73. 73.
    Jones RP, Vauthey JN, Adam R, Rees M, Berry D, Jackson R, et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg. 2012;99(9):1263–9.CrossRefGoogle Scholar
  74. 74.
    Ye YJ, Shen ZL, Sun XT, Wang ZF, Shen DH, Liu HJ, et al. Impact of multidisciplinary team working on the management of colorectal cancer. Chin Med J. 2012;125(2):172–7.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hepatobiliary Surgery, Digestive Diseases UnitAintree University HospitalLiverpoolUK

Personalised recommendations